Mechelen, Belgium; March 117, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America.

Pursuant to Belgian transparency legislation1, Galapagos received transparency notification from Bank of America Corporation on March 12, 2026. The notification indicates that Bank of America Corporation, as controlling entity, fell below the 5% threshold for of Galapagos’ voting rights on March 10, 2026, as a result of the disposal of equivalent financial instruments relating to Galapagos’ voting rights.

On March 12, 2026, Bank of America Corporation (taking into account the holding of its affiliates) owned 421,092 voting rights and 2,158,293 equivalent financial instruments, representing together 3.91% of Galapagos’ currently outstanding 65,897,071 shares.

Summary of the transactions:

Date on which the threshold was crossed
Date of notification
Direct voting rights after the transaction
Equivalent financial instruments after the transaction
Total (%)
voting rights
March 10, 2026
March 12, 2026
0.64%
3.28%
3.91%

Content of the notifications from Bank of America Corporation:
The notification dated March 12, 2026, contains the following information:

  • Date of notification: March 12, 2026
  • Date on which the threshold is crossed: March 10, 2026
  • Threshold of voting rights crossed (in %): 5%
  • Notification by: Bank of America Corporation
  • Denominator: 65,897,071
  • Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities
  • Notified details:

A) Voting Rights
Previous notification
After the transaction
# of voting rights
# of voting rights
% of voting rights
Holder of voting rights
Linked to securities
Not linked to securities
Linked to securities
Not linked to securities
Bank of America Corporation
0
0
0.00%
Bank of America, National Association
12,440
12,447
0.02%
Merrill Lynch International
128,053
225,319
0.34%
Managed Account Advisors LLC
3
3
0.00%
BofA Securities, Inc.
180,123
168,740
0.26%
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
14,462
14,462
0.02%
U.S. Trust Company of Delaware
121
121
0.00%
Subtotal
335,202
421,092
0.64%
TOTAL
421,092
0
0.64%
0.00%


B) Equivalent financial instruments
After the transaction
Holder of equivalent financial instruments
Type of financial instrument
Expiration date
Exercise period or date
# of voting rights that may be acquired if the instrument is exercised
% of voting rights
Settlement
Merrill Lynch International
Right to Recall
111,582
0.17%
physical
Merrill Lynch International
Rights of Use
6,579
0.01%
physical
BofA Securities, Inc.
Right to Recall
11,500
0.02%
physical
BofA Securities, Inc.
Rights of Use
1,876,489
2.85%
physical
Merrill Lynch International
Physical Call Option
19/06/2026
100,000
0.15%
physical
Bank of America, National Association
Swaps
15/04/2027
12,214
0.02%
cash
Bank of America, National Association
Swaps
29/02/2028
843
0.00%
cash
Bank of America, National Association
Swaps
15/10/2027
5
0.00%
cash
Merrill Lynch International
Swaps
15/01/2027
8,056
0.01%
cash
Merrill Lynch International
Swaps
30/04/2026
8,240
0.01%
cash
Merrill Lynch International
Swaps
02/07/2026
592
0.00%
cash
Merrill Lynch International
Swaps
01/11/2027
5,217
0.01%
cash
Merrill Lynch International
Swaps
15/04/2027
12,214
0.02%
cash
Merrill Lynch International
Swaps
30/06/2026
3,108
0.00%
cash
Merrill Lynch International
Swaps
31/03/2027
950
0.00%
cash
Merrill Lynch International
Swaps
29/01/2027
704
0.00%
cash
TOTAL
2,158,293
3.28%


TOTAL (A&B)
# of voting rights
% of voting rights
2,579,385
3.91%

The chain of control has been described at the end of the notification (section 11) and can be found here.

About Galapagos
Galapagos is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit www.glpg.com or follow us on LinkedIn or X.

For further information, contact Galapagos:
Investor Relations
Glenn Schulman

+1 412 522 6239
ir@glpg.com

Media
Media
Katie Morris
+1 952 288 6821
katiemorris@ententeinc.com

1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.

Attachment


Ämnen i artikeln

GALAPAGOS

Senast

26,20

1 dag %

−0,83%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån